Immuneering^® partners with leading pharmaceutical and biotech companies to investigate disease biology and therapeutic efficacy at the cellular and molecular level. Our MIT-trained team utilizes a proprietary approach to integrate data from a wide range of sources, generate unique and testable hypotheses, and provide insight into the biological mechanisms occurring in specific subsets of patients.

News Highlights

December 22, 2011: New England Journal of Medicine publishes Immuneering's hypothesis for increasing the number of patients considered good candidates for lebrikizumab treatment.

December 15, 2011: Clinical Cancer Research publishes Immuneering's hypothesis for combining siltuximab with inhibitors of EGFR signaling to achieve optimal response rates.

December 14, 2011: Defeating Alzheimer's event at MIT organized by Immuneering CEO Ben Zeskind.

December 5, 2011: Journal of Clinical Oncology publishes Immuneering's hypothesis for "Maximizing the Efficacy of Angiogenesis Inhibitors."

November 3-6, 2011: Immuneering co-sponsors the Workshop on Immunotherapy Combinations and other programs at the Society for Immunotherapy of Cancer's 26th Annual Meeting.

September 19, 2011: Journal of Translational Medicine review discusses Immuneering among "New Technologies for Biomarker Discovery."

June 29, 2011: Science publishes Immuneering's hypothesis "A Genetic Exploration of Alzheimer's Disease."